Clinical trials: Postmenopausal Osteopenia
Osteopenia, Postmenopausal Osteopenia
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides in Postmenopausal Women With Osteopenia
Osteoporosis is undoubtedly one of the most common diseases affecting older individuals with debilitating consequences. Osteopenia, defined as T-score between -1 and -2.5, has also been associated with increased risk of…
- Trial name
- NCT03999775
- Testing
- Calcium, vitamin D and bioactive collagen peptides supplement, Calcium and vitamin D supplement
- Volunteers
- 51 people
- Sponsor
- Ioannis K. Triantafyllopoulos, MD,MSci,PhD
Osteopenia, Postmenopausal Osteopenia
Design and Development of a Novel Food Supplement for Osteoporosis Based on Gut Microbiome Mechanisms
It is well proven that the intestinal microbe regulates bone metabolism by the absorption of calcium and other metallic trace elements.
- Trial name
- OSTEOME (NCT05421819)
- Testing
- Calcium and vitamin D supplement, Calcium, vitamin D and prebiotic supplement, Calcium, vitamin D and flavonoid supplement
- Where
- Greece
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Osteopenia, Osteoporosis
Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia
Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life.
- Trial name
- ACTLIFE (NCT03959995)
- Testing
- High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT), Wellness
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Postmenopausal Peri-implant Health, Postmenopausal Peri-mucositis
Evaluation of aMMP-8 and IL-1β Levels and Marginal Bone Loss Associated With Peri-Implant Mucositis and Peri-Implantitis in Postmenopausal Women
Peri-implant mucositis and peri-implantitis are among the major biological complications threatening the long-term success of dental implants.
- Conditions
- Postmenopausal Peri-implant Health, Postmenopausal Peri-mucositis, Postmenopausal Peri-implantitis
- Trial name
- NCT07785817
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medipol University
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Low Bone Mineral Density, Postmenopausal Osteoporosis
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
To investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (BMD) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.
- Trial name
- EFFECT (NCT05902078)
- Testing
- Eldecalcitol capsules, Calcitriol capsules
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Postmenopausal Osteoporosis
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
- Trial name
- NCT04366726
- Testing
- abaloparatide-sMTS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Radius Health, Inc.
Breast Cancer
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171314
- Testing
- Zoledronic acid, Letrozole
- Where
- 49 sites in Argentina, Belgium and 7 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Transition From Alendronate to Romosozumab (AMG 785)
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated…
- Trial name
- NCT01588509
- Testing
- Romosozumab
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis, Hypovitaminosis D
Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopause.
- Conditions
- Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism
- Trial name
- NCT05346419
- Testing
- Risedronate, Vitamin D
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- Hospital Regional 1o de Octubre
Osteoporosis
Effects of Parathyroid Hormone in Men With Osteoporosis
Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and…
- Trial name
- NCT00000427
- Testing
- Parathyroid hormone, Alendronate
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Osteopenia/Osteoporosis
To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia
Young postmenopausal women with osteopenia / or women with osteoporosis and a FRAX score below pharmacologic treatment indication have limited treatment options in the prevention of osteoporosis/treatment of osteopenia.
- Trial name
- NCT02527668
- Testing
- Calcifediol, Vitamin D3
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
- Trial name
- 2MD-3H-2B (NCT00715676)
- Testing
- DP001
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Deltanoid Pharmaceuticals
Bone Loss, Arteriosclerosis
Beneficial Effects of Long Term Menaquinone-7
From all K-vitamins, menaquinone-7 (MK-7) has been identified now as the most effective cofactor for the carboxylation reaction of Gla-proteins such as osteocalcin (in bone) and matrix-Gla protein (in the arterial vessel wall).
- Trial name
- NCT00642551
- Testing
- menaquinone-7
- Where
- Netherlands
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure, Arterial Hypertension
Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD
1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD). 2.
- Conditions
- Heart Failure, Arterial Hypertension, Osteopenia, Menopause
- Trial name
- Not aplicable (NCT06828211)
- Testing
- Trans-resveratrol extract from Polygonum Cuspidatum
- Where
- Ukraine
- Volunteers
- 80 people
- Sponsor
- OMNIFARMA LLC
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
High Intensity Multi-Modal Exercise Training in Postmenopausal Women
in Pakistan 9.9 million people are osteoporotic and 7.2 million amongst them are women. Globally after every 3 seconds there is occurrence of fragility fracture.In Pakistan females carries different risk factors based on distinct…
- Trial name
- HIT-MMEX (NCT04653350)
- Testing
- High Intensity Exercises, General Exercises
- Where
- 2 sites in Pakistan
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Bone Loss, Osteoporosis
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.
- Trial name
- NCT01159873
- Testing
- CEP-37251
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cephalon
Postmenopausal Osteoporosis, Osteopenia
Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
The overall objective of the study is to compare treatment with the ASTRA TECH Implant System, OsseoSpeed™ implant in the maxilla of postmenopausal women with and without systemic osteoporosis.
- Conditions
- Postmenopausal Osteoporosis, Osteopenia, Jaw, Edentulous, Partially
- Trial name
- NCT00745121
- Testing
- OsseoSpeed™
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 103 people
- Sponsor
- Dentsply Sirona Implants and Consumables